Transplant immunologyFR-0003
Felzartamab & transplant rejection
Antibody-mediated rejection (ABMR) can involve immune activity, tissue injury and chronic changes that need not evolve together. Established expression classifiers and transcript sets summarize these processes as continuous molecular scores. Felzartamab is an anti-CD38 monoclonal antibody. The supplied data come from a small randomized, double-blind, placebo-controlled trial with nine infusions over 20 weeks and follow-up to week 52. Earlier clinical findings motivated investigation of the molecular response and its persistence.
Scientific question: Among kidney transplant recipients with late active or chronic active ABMR, how does 20 weeks of felzartamab treatment, compared with placebo, affect the evolution of biopsy molecular phenotypes from baseline to weeks 24 and 52, in direction, magnitude and persistence?
